Literature DB >> 3044997

Direct cytotoxic action of Shiga toxin on human vascular endothelial cells.

T G Obrig1, P J Del Vecchio, J E Brown, T P Moran, B M Rowland, T K Judge, S W Rothman.   

Abstract

To help explain a role of the Shiga toxin family in hemorrhagic colitis and hemolytic-uremic syndrome in humans, it has been hypothesized that these toxins cause direct damage to the vascular endothelium. We now report that Shiga toxin purified from Shigella dysenteriae 1 does indeed have a direct cytotoxic effect on vascular endothelial cells in cultures. Human umbilical vein endothelial cells (HUVEC) in confluent monolayers were reduced 50% by 10(-8) M Shiga toxin after a lag period of 48 to 96 h. In comparison, nonconfluent HUVEC were reduced 50% by 10(-10) M Shiga toxin within a 24-h period. These data suggest that dividing endothelial cells are more sensitive to Shiga toxin than are quiescent cells in confluent monolayers. Both confluent and nonconfluent HUVEC specifically bound 125I-Shiga toxin. However, in response to the toxin, rates of incorporation of [3H]leucine into protein were more severely reduced in nonconfluent cells than in confluent cells. Toxin inhibition of protein synthesis preceded detachment of cells from the substratum. The specific binding of 125I-Shiga toxin to human endothelial cells and the cytotoxic response were both toxin dose dependent and neutralized by anti-Shiga toxin antibody. Heat-denatured Shiga toxin was without the cytotoxic effect. In addition, the complete culture system contained less than 0.1 ng of bacterial endotoxin per ml, as measured by the Limulus amoebocyte lysate test.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3044997      PMCID: PMC259575          DOI: 10.1128/iai.56.9.2373-2378.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  Inhibition of protein synthesis by Shiga toxin: activation of the toxin and inhibition of peptide elongation.

Authors:  J E Brown; M A Ussery; S H Leppla; S W Rothman
Journal:  FEBS Lett       Date:  1980-08-11       Impact factor: 4.124

2.  Clonal growth of epithelial cells from normal adult human bronchus.

Authors:  J F Lechner; A Haugen; H Autrup; I A McClendon; B F Trump; C C Harris
Journal:  Cancer Res       Date:  1981-06       Impact factor: 12.701

3.  Haemolytic-uraemic syndrome complicating shigella dystentery in south Indian children.

Authors:  P Raghupathy; A Date; J C Shastry; A Sudarsanam; M Jadhav
Journal:  Br Med J       Date:  1978-06-10

4.  Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes.

Authors:  F Koster; J Levin; L Walker; K S Tung; R H Gilman; M M Rahaman; M A Majid; S Islam; R C Williams
Journal:  N Engl J Med       Date:  1978-04-27       Impact factor: 91.245

5.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria.

Authors:  E A Jaffe; R L Nachman; C G Becker; C R Minick
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

6.  Characterization of Shigella dysenteriae 1 (Shiga) toxin purified by anti-Shiga toxin affinity chromatography.

Authors:  A D O'Brien; G D LaVeck; D E Griffin; M R Thompson
Journal:  Infect Immun       Date:  1980-10       Impact factor: 3.441

7.  Cytotoxicity of Shigella dysenteriae 1 for cultured mammalian cells.

Authors:  T L Hale; S B Formal
Journal:  Am J Clin Nutr       Date:  1980-11       Impact factor: 7.045

8.  Quantitative microtiter cytotoxicity assay for Shigella toxin.

Authors:  M K Gentry; J M Dalrymple
Journal:  J Clin Microbiol       Date:  1980-09       Impact factor: 5.948

9.  Subunit structure of Shigella cytotoxin.

Authors:  S Olsnes; R Reisbig; K Eiklid
Journal:  J Biol Chem       Date:  1981-08-25       Impact factor: 5.157

10.  Demonstration of vasoproliferative activity from mammalian retina.

Authors:  B M Glaser; P A D'Amore; R G Michels; A Patz; A Fenselau
Journal:  J Cell Biol       Date:  1980-02       Impact factor: 10.539

View more
  63 in total

1.  Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide.

Authors:  T Waddell; A Cohen; C A Lingwood
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  Glycolipid modification of alpha 2 interferon binding. Sequence similarity between the alpha 2 interferon receptor and verotoxin (Shiga-like toxin) B-subunit.

Authors:  C A Lingwood; S K Yiu
Journal:  Biochem J       Date:  1992-04-01       Impact factor: 3.857

3.  Serological responses to the B subunit of Shiga-like toxin 1 and its peptide fragments indicate that the B subunit is a vaccine candidate to counter action of the toxin.

Authors:  B Boyd; S Richardson; J Gariepy
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

4.  Monocyte chemoattractant protein 1, macrophage inflammatory protein 1 alpha, and RANTES recruit macrophages to the kidney in a mouse model of hemolytic-uremic syndrome.

Authors:  Tiffany R Keepers; Lisa K Gross; Tom G Obrig
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

5.  Chemokine expression in the monocytic cell line THP-1 in response to purified shiga toxin 1 and/or lipopolysaccharides.

Authors:  Lisa M Harrison; Christel van den Hoogen; Wilhelmina C E van Haaften; Vernon L Tesh
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 6.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid.

Authors:  L L Cooling; K E Walker; T Gille; T A Koerner
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

8.  The MAP kinase-activated protein kinase 2 (MK2) contributes to the Shiga toxin-induced inflammatory response.

Authors:  Jose B Saenz; Jinmei Li; David B Haslam
Journal:  Cell Microbiol       Date:  2009-11-27       Impact factor: 3.715

9.  Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro.

Authors:  C B Louise; T G Obrig
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

10.  Sensitivities and specificities of premier E. coli O157 and premier EHEC enzyme immunoassays for diagnosis of infection with verotxin (Shiga-like toxin)-producing Escherichia coli. The SYNSORB Pk Study investigators.

Authors:  A M Mackenzie; P Lebel; E Orrbine; P C Rowe; L Hyde; F Chan; W Johnson; P N McLaine
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.